Skip to main content
Premium Trial:

Request an Annual Quote

J&J Pharma R&D Signs On for Five More Years with Entelos

NEW YORK, March 16 (GenomeWeb News) - Johnson & Johnson Pharmaceutical Research & Development will collaborate with Entelos to research multiple therapeutic areas for five more years, Entelos said today.


Under the agreement, Entelos engineers and scientists will use the PhysioLab platforms to "support specific projects ... on behalf of J&JPRD and its affiliates," the company said in a statement.


Financial details were not provided.


As GenomeWeb News reported last week, Entelos is unalarmed about the recent downsizing at J&JPRD. The two companies also recently expanded a hemotology research collaboration.


"We believe J&JPRD's continued commitment to apply the power of biosimulation to the drug discovery and development decisions will lead to safer and more effective medicines for patients," Entelos president and CEO James Karis said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.